New evidence for nicotinic acid treatment to reduce atherosclerosis

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 10, 2010, Pages 1457-1467

  Montecucco, Fabrizio ^a   Quercioli, Alessandra ^a   Dallegri, Franco ^b   Viviani, Giorgio Luciano ^c   MacH, Franois ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

atherosclerosis; cardiovascular risk; cholesterol; inflammation; nicotinic acid

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CAROTENE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LAROPIPRANT; LEPTIN; MEVINOLIN; NICOTINIC ACID; SELENIUM; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOCYTE; ATHEROGENESIS; ATHEROSCLEROSIS; ENDOTHELIUM CELL; HEART PROTECTION; HUMAN; IMMUNOCOMPETENT CELL; LIVER CELL; NONHUMAN; REVIEW;

ANIMALS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPOLIPIDEMIC AGENTS; NIACIN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; TREATMENT OUTCOME;

EID: 77958100005     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.116     Document Type: Review

References (87)

1. Goldberger J. The etiology of Pellagra. Public Health Rep. 29, 1683-1686 (1914).
2. + precursor vitamins in human nutrition. Annu. Rev. Nutr. 28, 115-130 (2008).
3. Altschul R, Hoffer A, Stephen JD. Infuence of nicotinic acid on serum cholesterol in man. Arch. Biochem. 54(2), 558-559 (1955).
4. Damian DL. Photoprotective effects of nicotinamide. Photochem. Photobiol. Sci. 9(4), 578-585 (2010).
5. Knip M, Douek IF, Moore WP et al. European Nicotinamide Diabetes Intervention Trial Group. Safety of high-dose nicotinamide: a review. Diabetologia 43(11), 133 7-1345 (2000).
6. Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol. 48, 79-106 (2008).
7. Wise A, Foord SM, Fraser NJ et al. Molecular identifcation of high and low affnity receptors for nicotinic acid. J. Biol. Chem. 278(11), 9869-9874 (2003).
8. Tunaru S, Kero J, Schaub A et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 9(3), 352-355 (2003).
9. Soudijn W, van Wijngaarden I, Ijzerman AP. Nicotinic acid receptor subtypes and their ligands. Med. Res. Rev. 27(3), 417-433 (2007).
10. Mrochek JE, Jolley RL, Young DS, Turner WJ. Metabolic response of humans to ingestion of nicotinic acid and nicotinamide. Clin. Chem. 22(11), 1821-1827 (1976).
11. Pieper JA. Overview of niacin formulations: differences in pharmacokinetics, effcacy, and safety Am. J. Health Syst. Pharm. 60(13 Suppl. 2), S9-S14 (2003).
12. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am. J. Cardiol. 86(12A), 35L-40L (2000).
13. Iwaki M, Ogiso T, Hayashi H, Tanino T, Benet LZ. Acute dose-dependent disposition studies of nicotinic acid in rats. Drug Metab. Dispos. 24(7), 773-779 (1996).
14. Benyó Z, Gille A, Kero J et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced fushing. J. Clin. Invest. 115(12), 3634-3640 (2005).
15. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): effcacy, tolerability, and safety in hypercholesterolemic patients. Am. J. Cardiol. 82(12A), 29U-34U (1998).
16. Carlson LA. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int. J. Clin. Pract. 58(7), 706-713 (2004).
17. McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 65(18), 2719-2740 (2005).
18. Shepherd J, Betteridge J, Van Gaal L; European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr. Med. Res. Opin. 21(5), 665-682 (2005).
19. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch. Intern. Med. 164(7), 697-705 (2004).
20. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fbrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol. Ther. 126(3), 314-345 (2010).
21. Menon RM, González MA, Adams MH, Tolbert DS, Leu JH, Cefali EA. Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites. J. Clin. Pharmacol. 47(6), 681-688 (2007).
22. Sturino CF, O'Neill G, Lachance N et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7- fuoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl]-acetic acid (MK-0524). J. Med. Chem. 50(4), 794-806 (2007).
23. Cheng K, Wu TJ, Wu KK et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl Acad. Sci. USA 103(17), 6682-6687 (2006).
24. Lai E, De Lepeleire I, Crumley TM et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther. 81(6), 849-857 (2007).
25. Paolini JF, Mitchel YB, Reyes R et al. Effects of laropiprant on nicotinic acid-induced fushing in patients with dyslipidemia. Am. J. Cardiol. 101(5), 625-630 (2008).
26. Maccubbin D, Bays HE, Olsson AG et al. Lipid-modifying effcacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int. J. Clin. Pract. 62(12), 1959-1970 (2008).
27. Paolini JF, Bays HE, Ballantyne CM et al. Extended-release niacin/laropiprant: reducing niacin-induced fushing to better realize the beneft of niacin in improving cardiovascular risk factors. Cardiol. Clin. 26(4), 547-560 (2008).
28. Gleim G, Ballantyne CM, Liu N et al. Effcacy and safety profle of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br. J. Cardiol. 16, 90-97 (2009).
29. Clofbrate and niacin in coronary heart disease. JAMA 231(4), 360-381 (1975).
30. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Benefcial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257(23), 3233-3240 (1987).
31. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofbrate and nicotinic acid. Acta Med. Scand. 223(5), 405-418 (1988).
32. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323(19), 1289-1298 (1990).
33. Blankenhorn DH, Azen SP, Crawford DW et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 83(2), 438-447 (1991).
34. Blankenhorn DH, Selzer RH, Crawford DW et al. Benefcial effects of colestipol-niacin therapy on the common carotid artery Two-and four-year reduction of intima-media thickness measured by ultrasound. Circulation 88(1), 20-28 (1993).
35. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345(22), 1583-1592 (2001).
36. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110(23), 3512-3517 (2004).
37. Whitney EJ, Krasuski RA, Personius BE et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann. Intern. Med. 142(2), 95-104 (2005).
38. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin. 22(11), 2243-2250 (2006).
39. Thoenes M, Oguchi A, Nagamia S et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and infammatory markers in patients with the metabolic syndrome. Int. J. Clin. Pract. 61(11), 1942-1948 (2007).
40. Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering effcacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidaemia. J. Am. Coll. Cardiol. 51(16), 1564-1572 (2008).
41. Lee JM, Robson MD, Yu LM et al. Effects of high-dose modifed-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study J. Am. Coll. Cardiol. 54(19), 1787-1794 (2009).
42. Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361(22), 2113-2122 (2009).
43. Villines TC, Stanek EJ, Devine PJ et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) fnal results and the impact of medication adherence, dose, and treatment duration. J. Am. Coll. Cardiol. 55(24), 2721-2726 (2010).
44. Digby JE, Lee JM, Choudhury RP. Nicotinic acid and the prevention of coronary artery disease. Curr. Opin. Lipidol. 20(4), 321-326 (2009).
45. Lamon-Fava S, Diffenderfer MR, Barrett PH et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler. Thromb. Vasc. Biol. 28(9), 1672-1678 (2008).
46. Wang W, Basinger A, Neese RA et al. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am. J. Physiol. Endocrinol. Metab. 280(3), E540-E547 (2001).
47. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fbrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J. 31(2), 149-164 (2010).
48. Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review). J. Nutr. Biochem. 14(6), 298-305 (2003).
49. Zhang LH, Kamanna VS, Zhang MC, Kashyap ML. Niacin inhibits surface expression of ATP synthase ß chain in HepG2 cells: implications for raising HDL. J. Lipid. Res. 49(6), 1195-1201 (2008).
50. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am. J. Cardiol. 101(8A), 20B-26B (2008).
51. van der Hoorn JW, de Haan W, Berbée JF et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden. CETP mice. Arterioscler. Thromb. Vasc. Biol. 28(11), 2016-2022 (2008).
52. Guyton JR, Blazing MA, Hagar J et al. Extended-release niacin vs gemfbrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfbrozil Study Group. Arch. Intern. Med. 160(8), 1177-1184 (2000).
53. Morgan JM, Capuzzi DM, Baksh RI et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am. J. Cardiol. 91(12), 1432-1436 (2003).
54. Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confned to normotriglyceridemic patients. Arterioscler. Thromb. 11(1), 174-182 (1991).
55. Windler E, Schöffauer M, Zyriax BC. The signifcance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Diab. Vasc. Dis. Res. 4(2), 136-142 (2007).
56. Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin. Endocrinol. (Oxf.). 70(6), 815-828 (2009).
57. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term beneft with niacin. J. Am. Coll. Cardiol. 8(6), 1245-1255 (1986).
58. Warnholtz A, Wild P, Ostad MA et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis 204(1), 216-221 (2009).
59. Sorrentino SA, Besler C, Rohrer L et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with Type 2 diabetes mellitus but are improved after extended-release niacin therapy Circulation 121(1), 110-122 (2010).
60. Backes JM, Howard PA, Moriarty PM. Role of C-reactive protein in cardiovascular disease. Ann. Pharmacother. 38, 110-118 (2004).
61. Kashyap ML, McGovern ME, Berra K et al. Long-term safety and effcacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am. J. Cardiol. 89, 672-678 (2002).
62. Moon YS, Kashyap ML. Niacin extended-release lovastatin: combination therapy for lipid disorders. Expert Opin. Pharmacother. 3, 1768-1774 (2002).
63. Scheurig AC, Thorand B, Fischer B, Heier M, Koenig W. Association between the intake of vitamins and trace elements from supplements and C-reactive protein: results of the MONICA/KORA Augsburg study. Eur. J. Clin. Nutr. 62(1), 127-137 (2008).
64. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 193(2), 361-365 (2007).
65. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Adipokines and treatment with niacin. Metabolism 55(10), 1283-1285 (2006).
66. Linke A, Sonnabend M, Fasshauer M et al. Effects of extended-release niacin on lipid profle and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis 205(1), 207-213 (2009).
67. Plaisance EP, Grandjean PW, Brunson BL, Judd RL. Increased total and high-molecular weight adiponectin after extended-release niacin. Metabolism 57(3), 404-409 (2008).
68. Knopp RH, Retzlaff BM, Fish B et al. The SLIM Study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Infammatory Markers in Combined Hyperlipidemia. J. Clin. Lipidol. 3(3), 167-178 (2009).
69. Premkumar VG, Yuvaraj S, Vijayasarathy K, Gangadaran SG, Sachdanandam P. Serum cytokine levels of interleukin-1ß,-6,-8, tumour necrosis factor-α and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), ribofavin and niacin. Basic Clin. Pharmacol. Toxicol. 100(6), 387-391 (2007).
70. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler. Thromb. Vasc. Biol. 19(4), 1051-1059 (1999).
71. Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am. J. Cardiol. 100(11 A), S53-S61 (2007).
72. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J. Lipid. Res. 45(10), 1835-1845 (2004).
73. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 17(10), 2020-2028 (1997).
74. Zhang LH, Kamanna VS, Zhang MC, Kashyap ML. Niacin inhibits surface expression of ATP synthase β chain in HepG2 cells: implications for raising HDL. J. Lipid. Res. 49(6), 1195-1201 (2008).
75. Soga T, Kamohara M, Takasaki J et al. Molecular identifcation of nicotinic acid receptor. Biochem. Biophys. Res. Commun. 303(1), 364-369 (2003).
76. Carlson LA. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta. Med. Scand. 173, 719-722 (1963).
77. Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G, Judd RL. Niacin stimulates adiponectin secretion through the GPR109A receptor. Am. J. Physiol. Endocrinol. Metab. 296(3), E549-E558 (2009).
78. Digby JE, McNeill E, Dyar OJ, Lam V, Greaves DR, Choudhury RP. Anti-infammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis 209(1), 89-95 (2010).
79. Maciejewski-Lenoir D, Richman JG et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J. Invest. Dermatol. 126(12), 2637-2646 (2006).
80. Meyers CD, Liu P, Kamanna VS, Kashyap ML. Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin fush. Atherosclerosis 192(2), 253-258 (2007).
81. Knowles HJ, te Poele RH, Workman P, Harris AL. Niacin induces PPARγ expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem. Pharmacol. 71(5), 646-656 (2006).
82. Kostylina G, Simon D, Fey MF, Yousef S, Simon HU. Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death Differ. 15(1), 134-142 (2008).
83. Carson DA, Seto S, Wasson DB. Pyridine nucleotide cycling and poly(ADP-ribose) synthesis in resting human lymphocytes. J. Immunol. 138(6), 1904-1907 (1987).
84. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev. Immunol. 8(10), 802-815 (2008).
85. Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. Evidence that niacin inhibits acute vascular infammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler. Thromb. Vasc. Biol. 30(5), 968-975 (2010).
86. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 202(1), 68-75 (2009).
87. Tavintharan S, Lim SC, Sum CF. Effects of niacin on cell adhesion and early atherogenesis: biochemical and functional fndings in endothelial cells. Basic Clin. Pharmacol. Toxicol. 104(3), 206-210 (2009).